Table 3.
Development of ERCP Pancreatitis in Indomethacin and Control Groups
| EP (-) | EP (+) | Total | p | ||||
| n | % | n | % | n | % | 0.043 | |
| Indomethacin | 31 | 96.9 | 1 | 3.1 | 32 | 100 | |
| Control | 22 | 78.6 | 6 | 21.4 | 28 | 100 | |
| Total | 53 | 88.3 | 7 | 11.7 | 60 | 100 | |
Development of ERCP Pancreatitis in Indomethacin and Control Groups
| EP (-) | EP (+) | Total | p | ||||
| n | % | n | % | n | % | 0.043 | |
| Indomethacin | 31 | 96.9 | 1 | 3.1 | 32 | 100 | |
| Control | 22 | 78.6 | 6 | 21.4 | 28 | 100 | |
| Total | 53 | 88.3 | 7 | 11.7 | 60 | 100 | |